Rodney A. Beck
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Cancer Cells and Metastasis, Estrogen and related hormone effects, Advanced Breast Cancer Therapies
Most-Cited Works
- → Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy(2010)118 cited
- → A novel five-antibody immunohistochemical test for subclassification of lung carcinoma(2009)91 cited
- → Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials(2008)65 cited
- → Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study(2012)65 cited
- → A Search for Reliable Molecular Markers of Prognosis in Prostate Cancer(2012)38 cited
- → The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence(2010)38 cited
- → Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness(2011)27 cited
- → TLE3 as a candidate biomarker of response to taxane therapy(2009)27 cited
- → Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients(2015)6 cited
- → Abstract 3734: TLE3 expression is predictive of response to chemotherapy in NSCLC(2010)2 cited